{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:25:49Z","timestamp":1782487549208,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.det.2016.11.010","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T02:21:47Z","timestamp":1489717307000},"page":"219-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Depigmentation Therapies for Vitiligo"],"prefix":"10.1016","volume":"35","author":[{"given":"Pearl E.","family":"Grimes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Nashawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2016.11.010_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jaad.2004.01.007","article-title":"White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo","volume":"51","author":"Grimes","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib2","article-title":"Vitiligo: pathogenesis, clinical features, and diagnosis","author":"Grimes","year":"2016"},{"key":"10.1016\/j.det.2016.11.010_bib3","article-title":"Vitiligo: management and prognosis","author":"Grimes","year":"2016"},{"key":"10.1016\/j.det.2016.11.010_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2340\/00015555-1981","article-title":"Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo","volume":"95","author":"Kruger","year":"2015","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.det.2016.11.010_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/pde.12226","article-title":"Quality of life impairment in children and adolescents with vitiligo","volume":"31","author":"Silverberg","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.det.2016.11.010_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coi.2013.10.010","article-title":"Innate immune mechanisms in vitiligo: danger from within","volume":"25","author":"Richmond","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"10.1016\/j.det.2016.11.010_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0378-6323.90946","article-title":"Depigmentation therapies in vitiligo","volume":"78","author":"Gupta","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.det.2016.11.010_bib9","first-page":"248","article-title":"Vitiligo patients seeking depigmentation therapy: a case report and guidelines for psychological screening","volume":"91","author":"Grau","year":"2013","journal-title":"Cutis"},{"key":"10.1016\/j.det.2016.11.010_bib10","first-page":"57","article-title":"Depigmentation therapy for vitiligo in patients with Fitzpatrick skin type VI","volume":"89","author":"Black","year":"2012","journal-title":"Cutis"},{"key":"10.1016\/j.det.2016.11.010_bib11","first-page":"405","article-title":"A\u00a0depigmentatioin of the skin","volume":"8","author":"McNally","year":"1939","journal-title":"Industrial Med"},{"key":"10.1016\/j.det.2016.11.010_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.1939.72800350003010a","article-title":"Occupational leukoderma: preliminary report","volume":"113","author":"Oliver","year":"1939","journal-title":"JAMA"},{"key":"10.1016\/j.det.2016.11.010_bib13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archderm.1940.01490180002001","article-title":"Occupational leukoderma","volume":"42","author":"Oliver","year":"1940","journal-title":"Arch Derm Syphilol"},{"issue":"9","key":"10.1016\/j.det.2016.11.010_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archderm.1985.01660090055013","article-title":"Dermatitis produced by applications of monobenzone in patients with active vitiligo","volume":"121","author":"Nordlund","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CMR.0b013e328343f542","article-title":"Topical application of bleaching phenols: in\u00a0vivo studies and mechanism of action relevant to melanoma treatment","volume":"21","author":"Hariharan","year":"2011","journal-title":"Melanoma Res"},{"key":"10.1016\/j.det.2016.11.010_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/jid.2009.214","article-title":"Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation","volume":"130","author":"Hariharan","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1755-148X.2011.00878.x","article-title":"Monobenzone induced depigmentation: from enzymatic blockade to autoimmunity","volume":"24","author":"Van doon Boom","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"10.1016\/j.det.2016.11.010_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.1977.tb14275.x","article-title":"Monobenzylether of hydroquinone","volume":"97","author":"Mosher","year":"1977","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib19","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/bjd.13642","article-title":"Topical monobenzyl ether of hydroquinone is an effective and safe treatment for depigmentation of extensive vitiligo in the medium term: a retrospective cohort study of 53 cases","volume":"172","author":"Tan","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1600-0625.2006.00441.x","article-title":"Retinoic acid synergetically enhances the melanocytic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin","volume":"15","author":"Kasraee","year":"2006","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2016.11.010_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archopht.1983.01040010066010","article-title":"Corneal and conjunctival effects of monobenzone in patients with vitiligo","volume":"101","author":"Hedges","year":"1983","journal-title":"Arch Ophthalmol"},{"issue":"5 pt. 1","key":"10.1016\/j.det.2016.11.010_bib22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1067\/mjd.2000.103813","article-title":"Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser","volume":"42","author":"Njoo","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2230.2009.03412.x","article-title":"Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole","volume":"35","author":"Di Nuzzo","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"10.1016\/j.det.2016.11.010_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1524-4725.1989.tb03182.x","article-title":"Variations and comparisons in medium-depth chemical peeling","volume":"15","author":"Brody","year":"1989","journal-title":"J\u00a0Dermatol Surg Oncol"},{"key":"10.1016\/j.det.2016.11.010_bib25","first-page":"112","article-title":"Induction of depigmentation in a universal vitiligo patient with combination of cryotherapy and phenol","volume":"19","author":"Kavuossi","year":"2009","journal-title":"J\u00a0Pak Assoc Dermatol"},{"issue":"4","key":"10.1016\/j.det.2016.11.010_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1590\/S0365-05962005000400013","article-title":"Depigmentation therapy for generalized vitiligo with topical 88% phenol solution","volume":"80","author":"Zanini","year":"2005","journal-title":"An Bras Dermatol"},{"issue":"11","key":"10.1016\/j.det.2016.11.010_bib27","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/jid.2012.181","article-title":"Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8","volume":"132","author":"Toosi","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1468-3083.2010.03876.x","article-title":"Depigmentation therapies for normal skin in vitiligo universalis","volume":"25","author":"Alghamdi","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.010_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00000637-199209000-00007","article-title":"Treatment of superficial cutaneous pigmented lesions by melanin-specific selective photothermolysis using the Q-switched ruby laser","volume":"29","author":"Nelson","year":"1992","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.det.2016.11.010_bib30","first-page":"1043","article-title":"Use of the Q-switched 755 nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo","volume":"30","author":"Rao","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2016.11.010_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0974-2077.112670","article-title":"Depigmentation therapy with Q-switched Nd:YAG laser in universal vitiligo","volume":"6","author":"Majid","year":"2013","journal-title":"J\u00a0Cutan Aesthet Surg"},{"key":"10.1016\/j.det.2016.11.010_bib32","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/bjd.12571","article-title":"Q-switched laser depigmentation in vitiligo, most effective in active disease","volume":"169","author":"Komen","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jdv.12762","article-title":"Laser (755 nm) and cryotherapy as depigmentation treatments for vitiligo: a comparative study","volume":"29","author":"Van Geel","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.010_bib34","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.20267","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"100","author":"Leong","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.det.2016.11.010_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1658-3876(09)50026-X","article-title":"Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia","volume":"2","author":"Aleem","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.det.2016.11.010_bib36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2004.10.861","article-title":"Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts","volume":"52","author":"Zirvi","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/jid.2008.184","article-title":"Imiquimod, a toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes","volume":"129","author":"Kang","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.010_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00403-009-1012-0","article-title":"Imiquimod induces apoptosis of human melanocytes","volume":"302","author":"Kim","year":"2010","journal-title":"Atch Dermatol Res"},{"key":"10.1016\/j.det.2016.11.010_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.1990.tb06306.x","article-title":"Persistent vitiligo induced by diphencyprone","volume":"123","author":"Duhra","year":"1990","journal-title":"Br J Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T12:54:07Z","timestamp":1535979247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863516301371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0733863516301371"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2016.11.010","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depigmentation Therapies for Vitiligo","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}